Last Modified: April 6, 2005
Conference Dates: May 19-20, 2005
Conference Location: Best Western Boston, The Inn at Longwood Medical, 342 Longwood Avenue, Boston, MA
Sponsoring Group: Dana-Farber/Partners CancerCare, Harvard Medical School, Multiple Myeloma Research Foundation
Conference Web Page URL: www.multiplemyeloma.org/medical_programs
Who Should Attend: Patients (May 19); Hematologists, Medical Oncologists, Oncology Nurses, Internists with Newly Diagnosed Patients
Conference Fees: Free Patient Program, $25 Professional Registration
Continuing Education: Yes. 4 category 1 credits available for physicians.
Jan 30, 2015 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Jan 30, 2015
Dec 13, 2010